MOL - MOLECULE GROUP PLC
Director/PDMR Transaction
· RNS
Summary
Brendan O’Brien acquired 41,500 Molecule shares at an average price of £2.13 (18,300 at £2.14 on 08‑Oct‑2026 and 23,200 at £2.12 on 12‑Oct‑2026) and now holds 591,500 shares (2.2% of issued capital). Molecule is executing a buy‑and‑build strategy to create a regulated UK ePharmacy (acquisitions: CloudRx, Webmed, Hyperdrug in Mar‑2026), operating a diversified, profitable B2B prescription‑fulfilment and B2C digital pharmacy platform with recurring revenues and strong cash generation; growth is expected via further M&A, market expansion and asset investment, with key risks from M&A execution/integration and regulatory/competitive pressures.
Announcement
Molecule Group plc
(the “Company”, “Group” or “Molecule”)
Director/PDMR Transaction
Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, announces that Brendan O’Brien, Chief Operating Officer, has acquired a total of 41,500 ordinary shares of 10 pence each in the Company ("Ordinary Shares") at an average price of £2.13 per Ordinary Share. Following the purchases, Mr O’Brien holds 591,500 Ordinary Shares, representing 2.2% of the Company’s issued share capital.
The Notification of Dealings are set out below.
The following transactions have been notified to the Company pursuant to Article 19.1(a) of the UK Market Abuse Regulation ("MAR"). This notification is issued in accordance with Article 19.3 of MAR.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Brendan O’Brien |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/Status:
|
Chief Operating Officer |
||||
|
b) |
Initial Notification/Amendment:
|
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Molecule Group plc |
||||
|
b) |
LEI: |
213800W5TPGBRC2V7L20 |
||||
|
4. |
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. |
|||||
|
a) |
Description of the financial instrument:
|
Ordinary Shares of 10 pence each
|
||||
|
b) |
Identification code: |
ISIN: GB00BTQLZH16
|
||||
|
b) |
Nature of the transaction:
|
Acquisition of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated volume: Price: |
Single Transaction |
||||
|
e) |
Date of the Transaction: |
08-10-2026 |
||||
|
f) |
Place of the Transaction: |
XLON:AIM |
||||
|
4. |
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. |
|||||
|
a) |
Description of the financial instrument:
|
Ordinary Shares of 10 pence each
|
||||
|
b) |
Identification code: |
ISIN: GB00BTQLZH16
|
||||
|
b) |
Nature of the transaction:
|
Acquisition of Ordinary Shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated volume: Price: |
Single Transaction |
||||
|
e) |
Date of the Transaction: |
12-10-2026 |
||||
|
f) |
Place of the Transaction: |
XLON:AIM |
||||
For further information please contact:
|
Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Finance Officer Brendan O’Brien, Chief Operating Officer |
Email: corporate@molecule.co.uk |
|
Canaccord Genuity Limited Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott |
Tel: +44 (0) 20 7523 8000 |
|
Alma Strategic Communications Justine James / Sam Modlin / Will Merison |
Email: molecule@almastrategic.com Tel: +44 (0) 20 3405 0205 |
Notes to Editors
Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.
The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.